O’Neill et al. (2013) suggested that blocking the epidermal growth factor receptor (EGFR) results in PI3K-PKB inhibition and increases FOXO3a activation, which provides a new and valuable treatment strategy for breast cancer, prostate cancer, and ovarian cancer. Here, EGFR is linked to ovarian carcinoma.